Fagron SA

FAGR

Equity

ISIN BE0003874915 / Valor 3425437

Euronext - Euronext Brussels (2025-11-21)

EUR 20.70+0.98%

Fagron SA
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Fagron SA is a prominent player in the pharmaceutical industry, specializing in pharmaceutical compounding, which involves creating personalized medication solutions tailored to individual patient needs. The company operates in a knowledge-intensive niche market, focusing on enhancing personalized medicine by collaborating closely with prescribers and pharmacists. Fagron's global initiative, Formulary, provides a wide array of customized formulas that cater to specific medical indications, thereby supporting healthcare professionals in delivering tailored treatment options. Additionally, Fagron emphasizes education and training through its Fagron Academies, which are established in various countries to inform and train healthcare providers about the intricacies of compounding. This strategic approach underscores Fagron's commitment to improving patient health outcomes by making personalized medicine more accessible.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

In Q3 2025, Fagron SA recorded revenues of €228.2 million, marking a 6.4% increase on a reported basis and a 10.3% growth at constant exchange rates (CER). This growth was driven by robust performance across all regions and segments.

Operational Excellence

The FDA inspection at Fagron's Wichita facility confirmed the effectiveness of corrective actions, with no repeat observations compared to the 2024 inspection. Additionally, the approved capacity expansion is expected to generate approximately €25 million in additional revenue.

Market Expansion and M&A Activity

Fagron SA successfully obtained competition clearance for Purifarma and Injeplast in Brazil, enhancing its portfolio and capabilities in the region. The company continued its acquisition momentum by signing the University Compounding Pharmacy in North America, bringing the total number of acquisitions announced year-to-date to eight.

Full-Year Outlook

The company has confirmed its revenue guidance for the full year 2025, projecting between €930 and €950 million. Fagron SA also expects a slight improvement in profitability compared to the previous year, maintaining its medium-term growth objectives.

Summarized from source with an LLMView Source

Key figures

13.2%1Y

66.3%3Y

8.66%5Y

Performance

21.4%1Y

21.9%3Y

24.5%5Y

Volatility